Alkylating Agents Market Key Trends and Opportunity Analysis 2025
Added: (Wed Feb 07 2018)
Pressbox (Press Release) -
Cancer has been a growing concern affecting more than eight million people across the globe. Statistics published by the World Health Organization stated that more than 60% of cancer cases occur in Africa, Asia, and South and Central America. The organization also projected that the number of cancer cases could reach 22 million by 2032. Lung, liver, stomach, colorectal, and breast are among the leading cause of cancer deaths. The high mortality rate and wide prevalence of cancer have driven scientists to engage in the discovery of better treatment options of the disease. Alkylating agents were among the earliest classes of drugs available for treating cancer. These are the first nonhormonal drugs successfully used in the cancer treatment.
Report Overview @ https://www.transparencymarketresearch.com/alkylating-agents-market.html
Traditionally, alkylating agents are grouped into SN1 and SN2 types. The SN1 agents directly react with biological molecules. The SN2 type agents are those that form an intermediate, which then react with the biological molecules. Alkylating agents act by damaging the DNA strands and prevent cancer cells from replicating. These agents show activity against the cancer cell during each phase of its life cycle, thus making alkylating agents desirable for treating a wide range of cancers. As alkylating agents act by altering the DNA strands, prolonged use of about 5 years to 10 years of these agents can lead to bone marrow damage, and, in rare instances, it might lead to acute leukemia. Temodar (temozolomide) by Merck, Treanda (bendamustine) by Teva Pharma, and Eloxatin (Oxaliplatin) by Sanofi are the major drugs in this class. Temodar and Eloxatin lost their exclusivity in 2013 and 2012, respectively.
The rising prevalence of different cancer types such as lymphoma, carcinoma, leukemia, and bladder cancer is a major growth driver for the global alkylating agents market. Sedentary and unhealthy lifestyles and environmental changes are factors leading to the increasing prevalence of cancer. Alkylating agents are used in chemotherapy for 100 different cancer types known till date. In addition, rising awareness about various forms of cancers and their treatment is one of the key factors for the growth of the global alkylating agents market.
The global alkylating agents market has been segmented based on type, route of administration, distribution channel, and region. In terms of type, the market is segmented into five major classes: nitrogen mustards, alkyl sulfonates, nitrosoureas, triazines, and ethylenimines. The dosage and schedule of each type of alkylating agent depend on the patientís overall health, weight and cancer type which is to be treated. Nitrogen mustards include drugs such as mechlorethamine, ifosfamide, melphalan, chlorambucil, and cyclophosphamide. Nitrosoureas class of alkylating agents consists drugs such as streptozocin, carmustine, and lomustine.
Download Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=35678
Alkyl sulfonates include drugs such as busulfan, treosulfan, and mannosulfan. Ethylenimines include drugs such as thiotepa and altretamine. Triazenes include drugs such as dacarbazine and temozolomide. In terms of route of administration, the market is segmented into oral route and intravenous route. In terms of distribution channel, the market is divided into hospital pharmacies, retail pharmacies, online retailers, and private clinics.
Geographically, the global alkylating agents market is segmented into five key regions: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America accounts for the largest market share owing to high research and development, favorable reimbursement policies, and availability of advanced health care infrastructure. The implementation of the Affordable Care Act has significantly posed limitations to hospitals as well as pharmaceutical companies with respect to costing of new drugs.
Europe is the second largest market globally due to the presence of high quality scientific companies and research organizations. However, lack of proper reimbursement policies and regulatory framework pertaining to new drug development are key restraints which might hamper the market growth in Europe.
Enquiry for discount on this report @ https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=35678
Key players operating in the global alkylating agents market include Merck & Co., Inc., Cipla Inc., and Pfizer Inc.
Transparency Market Research (TMR) is a market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. TMRís experienced team of analysts, researchers, and consultants, use proprietary data sources and various tools and techniques to gather, and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such as pharmaceuticals, chemicals, energy, food & beverages, semiconductors, med-devices, consumer goods and technology. These reports provide in-depth analysis and deep segmentation to possible micro levels. With wider scope and stratified research methodology, TMRís syndicated reports strive to provide clients to serve their overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
USA - Canada Toll Free: 866-552-3453